Dr. Keith August

Children’s Mercy Hospital, Kansas City, Missouri

Dr. Sholler is the Chair of Beat Childhood Cancer (formerly NMTRC), the Endowed Director of the Haworth Family Innovative Therapeutics Clinic, and Director of Pediatric Oncology Research at Helen DeVos Children’s Hospital.

Appointments: (816) 302-6808 to schedule.

2401 Gillham Road
Kansas City, MO 64108
Phone: (816) 302-6808
E-mail: kjaugust@cmh.edu

Dr. August is a pediatric oncologist and Director of the Experimental Therapeutics in Pediatric
Cancer Program at Children’s Mercy Hospital in Kansas City, Missouri. The Experimental
Therapeutics Program offers a number of early phase clinical trials to local and regional patients,
including a number of Beat Childhood Cancer trials.

August 1998 – May 2002	University of Oklahoma Medical School, Oklahoma City, OK Doctor of Medicine
July 2002 – June 2005	University of Louisville, Louisville, KY Pediatric Residency, Kosair Children’s Hospital
July 2005 – June 2008	Emory University, Atlanta, GA Pediatric Hematology/Oncology Fellowship Children’s Hospitals of Atlanta
September 2006 – May 2008	Emory University, Atlanta, GA Masters of Science and Clinical Research Rollins School of Public Health

Cooper TM, Sison EAR, Baker SD, Li L, Ahmed A, Trippett T, Gore L, Macy ME, Narendran A, August K, Absalon MJ, Boklan J, Pollard J, Magoon D, Brown PA. A Phase 1 Study of the CXCR4 Antagonist Plerixafor in Combination with High-Dose Cytarabine and Etoposide in Children with Relapsed or Refractory Acute Leukemias on Myelodysplastic Syndrome: A Pediatric Oncology Experimental Therapeutics Investigator’ Consortium Study (POE 10-03). Pediatric Blood and Cancer. 2017 Epub 04/17/2017.

Tolbert JA, Bai S, Abdel-Rahman SM, August KJ, Weir SJ, Kearns GL, Neville KA. Pharmacokinetics of Two 6-mercaptopurine Liquid Formulations in Children with Acute Lymphoblastic Leukemia. Pediatric Blood Cancer. Epub 03/10/2017.

Villanueva MA, August KJ. Early Discharge of Neutropenic Pediatric Oncology Patients Admitted with Fever. Pediatric Blood and Cancer. 2016: 63(10): 1829-33.

Cooper TM, Cassar J, Eckroth E, Malvar J, Sposto R, Gaynon P, Chang BH, Gore L, August JK, Pollard JA, Dubois SG, Silverman LB, Oesterheld J, Gammon G, Magoon D, Annesley CE, Brown PA. A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. Clinical Cancer Research. 2016; 22(16): 4014-22.

Mueller EL, Hall M, Shah SS, August KJ, Radhi MA, Macy ML. Characteristics of Children With Cancer Discharged or Admitted From the Emergency Department. Pediatric Blood and Cancer. 2016; 63(5): 853-8.

August KJ, Chiang KY, Qayed M, Dulson A, Worthington-White D, Cole CR, Horan JT. Relative Defects in Mucosal Immunity Predict Acute Graft-Versus-Host Disease. Biology of Blood and Marrow Transplantation. 2014; 20(7): 1056-1059.

August KJ, Narendran A, Neville KA. Pediatric Relapsed or Refractory Leukemia: New Pharmacotherapeutic Developments and Future Directions. Drugs. 2013; 73(5):439-461.

August KJ, Chiang KY, Bostick RM, Flanders WD, Waller EK, Langston A, Worthington-White D, Rowland P, Moore KF, Khoury HJ, Horan JT. Biomarkers of Immune Activation to Screen for Severe, Acute GVHD. Bone Marrow Transplantation. 2011; 46(4): 601-604.

August KJ, Dalton A, Katzenstein HM, George B, Olson TA, Wasilewski-Masker K, Rapkin LB. The Use of Zoledronic Acid in Pediatric Cancer Patients. Pediatric Blood and Cancer. 2011; 56:610-614.